An observational study in Breast Cancer Stage I and Triple Negative Breast Cancer (TNBC), sponsored by The Netherlands Cancer Institute. Recruiting at 28 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by The Netherlands Cancer Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands — 8 open to participants now, 14 under way, 4 of them phase 3. Triple Negative Breast Neoplasms · Netherlands.
Among the 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands, this one is one of 4 that started in 2025, is the only observational one, reaches primary completion later than 13 of the 13 other live ones, and was the 28th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →8 of the 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 18–70
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Argentina and 32 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Netherlands, United States, Australia and 7 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Netherlands, United States, Belgium and 7 more countries
Ages 18–100
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 14 · Phase 3 5
First in 2011; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 490 is above the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 201 across the 31 interventional studies, 490 across the 1 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 32 have an industry lead sponsor. The 10 most frequent:
The Netherlands Cancer Institute is the lead sponsor of 231 studies on the registry; 66 are open to participants now.
The Netherlands Cancer Institute has 4 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Triple Negative Breast Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT04954599Maastricht University Medical CenterPhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Triple Negative Breast Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment. In addition, the investigation looks at whether the omission of chemotherapy ensures a better quality of life. Participants decide, in consultation with their treating physician, whether they choose to be treated with adjuvant chemotherapy or not.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
This study's planned enrollment of 490 is above the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.
Browse Triple Negative Breast Neoplasms studies →The Netherlands Cancer Institute is the lead sponsor of 231 studies on the registry; 66 are open to participants now.
Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
patients with pathological stage I TNBC (pT1a/b/cN0) and a high sTIL score (defined as ≥50% for patients ≥40 years; ≥75% for patients \<40 years)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pathological stage I TNBC (according to the TNM staging 8th edition):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients will be treated with surgery and adjuvant radiotherapy following local/national guidelines, while chemotherapy will be omitted
Other: No adjuvant chemotherapy
patients will be treated with surgery, adjuvant radiotherapy and adjuvant chemotherapy following local/national guidelines
Drug: Adjuvant chemotherapy
adjuvant chemotherapy according to local/ national guidelines
Also known as: according to local/ national guidelines
no adjuvant chemotherapy
Disease recurrence Free Interval (DRFI) - optimalisation cohort per-protocol population
Number of patients with distant recurrence or death in per-protocol population of the optimisation cohort
Time frame: up to 96 months after inclusion of the last patient
Disease recurrence Free Interval (DRFI) - optimalisation cohort intention to treat population
Number of patients with distant recurrence or death in intention to treat population of the optimisation cohort
Time frame: up to 96 months after inclusion of the last patient
Disease recurrence Free Interval (DRFI) - control cohort
Number of patients with distant recurrence or death in control cohort
Time frame: up to 96 months after inclusion of the last patient
Invasive disease-free survival (IDFS) - optimalisation cohort per-protocol population
Number of patients with breast tumor recurrence or death in the per-protocol population of the optimisation cohort
Time frame: up to 96 months after inclusion of the last patient
Invasive disease-free survival (IDFS) - optimalisation cohort intention-to-treat population
Number of patients with breast tumor recurrence or death in the the intention-to-treat population of the optimisation cohort
Time frame: up to 96 months after inclusion of the last patient
Invasive disease-free survival (IDFS) - control cohort
Number of patients with breast tumor recurrence or death in the control cohort
Time frame: up to 96 months after inclusion of the last patient
disease recurrence free survival (DRFS) - optimalisation cohort per-protocol population
time between inclusion and first distant recurrence or death from any cause in the per-protocol population of the optimisation cohort
Time frame: up to 96 months after inclusion of the last patient
disease recurrence free survival (DRFS) - optimalisation cohort the intention-to-treat population
time between inclusion and first distant recurrence or death from any cause in the intention-to-treat population of the optimisation cohort population of the optimisation cohort
Time frame: up to 96 months after inclusion of the last patient
disease recurrence free survival (DRFS) - control cohort
time between inclusion and first distant recurrence or death from any cause in the control cohort
Time frame: up to 96 months after inclusion of the last patient
Recurrence-free survival (RFS) - optimalisation cohort per-protocol population
time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the per-protocol population of the optimisation cohort;
Time frame: up to 96 months after inclusion of the last patient
Recurrence-free survival (RFS) - optimalisation cohort the intention-to-treat population
time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the the intention-to-treat population of the optimisation cohort;
Time frame: up to 96 months after inclusion of the last patient
Recurrence-free survival (RFS) - control cohort
time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the control cohort;
Time frame: up to 96 months after inclusion of the last patient
Overal Survival (OS) - optimalisation cohort per-protocol population
time between inclusion and death from any cause in the per-protocol population of the optimisation cohort;
Time frame: up to 96 months after inclusion of the last patient
Overal Survival (OS) - optimalisation cohort intention-to-treat population
time between inclusion and death from any cause in the the intention-to-treat population of the optimisation cohort;
Time frame: up to 96 months after inclusion of the last patient
Overal Survival (OS) - control cohort
time between inclusion and death from any cause in the control cohort;
Time frame: up to 96 months after inclusion of the last patient
Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-C30
Difference in QoL assessed with the EORTC QLQ-C30 questionnaires between the optimisation and the control group. A higher score indicates a higher symptom burden.
Time frame: up to 2 years after inclusion
Health related Quality of Life (HRQoL) - (European Organisation on Research and Treatment of Cancer) EORTC questionnaire QLQ-BR45
Difference in QoL assessed with the EORTC QLQ-BR45 questionnaires between the optimisation and the control group. A higher score indicates a higher symptom burden.
Time frame: up to 2 years after inclusion
Fear of recurrence
Assessed with questionnaires to determine the difference in optimisation and control group
Time frame: up to 2 years after inclusion
Worries about health
Assessed with questionnaires to determine the difference in optimisation and control group. A higher score indicates a higher symptom burden.
Time frame: up to 2 years after inclusion
Cost effectiveness measured by quality-adjusted-life years (QALYs)
Measured per Quality-Adjusted Life Years (QALYs)
Time frame: up to 2 years after inclusion
Cost effectiveness measured per incremental cost-effectiveness ratio (ICER)
Measured per incremental cost-effectiveness ratio (ICER)
Time frame: up to 2 years after inclusion
Plan to share: No — no IPD plan
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Sep 2032, 89 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Triple Negative Breast Neoplasms →
The Netherlands Cancer Institute →